The Phase 3 study investigating atezolizumab for non-small cell lung cancer (NSCLC) reached primary completion on December 30, 2025. This trial, NCT05047250, focuses on chemotherapy-naïve patients with high PD-L1 expression Stage IV non-squamous or squamous NSCLC.
Background
Atezolizumab (also known as Tecentriq) is being evaluated in this study for its efficacy and safety in patients with Stage IV non-squamous or squamous non-small cell lung cancer. The trial specifically targets patients who are chemotherapy-naïve and exhibit high PD-L1 expression, without a sensitizing EGFR mutation or ALK translocation.
Trial design
The study, identified as NCT05047250, is a Phase 3, single-arm, multicenter trial. It enrolled 60 participants diagnosed with Non-Small Cell Lung Cancer. The intervention being studied is atezolizumab. The trial's primary objective is to evaluate the efficacy and safety of atezolizumab in the specified patient population.
What this means
The primary completion of this Phase 3 trial signifies that all participants have completed their planned course of treatment and follow-up for the primary outcome measures. The next steps typically involve data analysis to assess the efficacy and safety profile of atezolizumab in this specific population of patients with advanced NSCLC. The findings from this study will be crucial for understanding the potential role of atezolizumab as a first-line treatment option for chemotherapy-naïve patients with high PD-L1 expression.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05047250, titled "A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer," was posted with a primary completion date of 2025-12-30 on clinicaltrials.gov.